Observational studyHaematologica2018
Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study.
Observational study in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Rare Extraoral Plasmablastic Lymphoma in the Context of HIV and Toxoplasmosis: A Detailed Case Analysis With Therapeutic Insights.Clinical case reports · 2025Article
- Clinicopathological features and prognostic factors of AIDS-related lymphoma: a retrospective single-center study in China.Annals of hematology · 2025Article
- Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025Review
- Immune Characteristics and Immunotherapy of HIV-Associated Lymphoma.Current issues in molecular biology · 2024Review
- Recent advancements inAmerican journal of nuclear medicine and molecular imaging · 2024Review
- Plasmablastic lymphoma: current knowledge and future directions.Frontiers in immunology · 2024Review
- A promising prognostic model for predicting survival of patients with HIV-related diffuse large B-cell lymphoma in the cART era.Cancer medicine · 2023Observational
- Hemophagocytic lymphohistiocytosis in HIV-associated lymphoproliferative disorders.Annals of hematology · 2022Article
- Hypoalbuminemia predicts inferior outcome in patients with AIDS-related lymphoma.Infectious agents and cancer · 2022Article
- HIV-Associated Lymphomas: Progress and New Challenges.Journal of clinical medicine · 2022Review
- A Novel Prognostic Score Including the CD4/CD8 for AIDS-Related Lymphoma.Frontiers in cellular and infection microbiology · 2022Article
- Review
- Altered Spectrum of Lymphoid Neoplasms in a Single-Center Cohort of Common Variable Immunodeficiency with Immune Dysregulation.Journal of clinical immunology · 2021Article
- Clinical observations of bone marrow transfusion for promoting bone marrow reconstruction after chemotherapy for AIDS-related lymphoma.BMC immunology · 2021Article
- The Value of Nutritional Status in the Prognostic Analysis of Patients with AIDS-Related Lymphoma.Infection and drug resistance · 2021Article
- Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial.Frontiers in immunology · 2021Article
- The Changing Landscape of Lymphoma Associated with HIV Infection.Current oncology reports · 2020Review
- Tumor lysis syndrome as a risk factor for very early mortality in HIV-associated non-Hodgkin's lymphoma: A 10-year single-center experience.Journal of the Chinese Medical Association : JCMA · 2020Article
- Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party.Bone marrow transplantation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 17 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Outcome of HIV-infected patients with AIDS-related lymphomas has improved during recent years. However, data on incidence, risk factors, and outcome of relapses in AIDS-related lymphomas after achieving complete remission are still limited. This prospective observational multicenter study includes HIV-infected patients with biopsy- or cytology-proven malignant lymphomas since 2005. Data on HIV infection and lymphoma characteristics, treatment and outcome were recorded. For this analysis, AIDS-related lymphomas patients in complete remission were analyzed in terms of their relapse- free survival and potential risk factors for relapses. In total, 254 of 399 (63.7%) patients with AIDS-related lymphomas reached a complete remission with their first-line chemotherapy. After a median follow up of 4.6 years, 5-year overall survival of the 254 patients was 87.8% (Standard Error 3.1%). Twenty-nine patients relapsed (11.4%). Several factors were independently associated with a higher relapse rate, including an unclassifiable histology, a stage III or IV according to the Ann Arbor Staging System, no concomitant combined antiretroviral therapy during chemotherapy and R-CHOP-based compared to more intensive chemotherapy regimens in Burkitt lymphomas. In conclusion, complete remission and relapse rates observed in our study are similar to those reported in HIV-negative non-Hodgkin lymphomas. These data provide further evidence for the use of concomitant combined antiretroviral therapy during chemotherapy and a benefit from more intensive chemotherapy regimens in Burkitt lymphomas. Modifications to the chemotherapy regimen appear to have only a limited impact on relapse rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.